Advertisement

The Editor's Roundtable: Pathophysiology and Management of Hyponatremia and the Role of Vasopressin Antagonists

  • Vincent E. Friedewald
    Correspondence
    Corresponding author: Tel: 512-264-1611; fax: 512-264-7034
    Affiliations
    Associate Editor, The American Journal of Cardiology, Adjunct Senior Research Professor, Indiana University School of Medicine, Indianapolis, Indiana, and Research Professor, College of Science, University of Notre Dame, Notre Dame, Indiana
    Search for articles by this author
  • Michael Emmett
    Affiliations
    Chairman of Internal Medicine, Baylor University Medical Center, Dallas, Texas
    Search for articles by this author
  • Mihai Gheorghiade
    Affiliations
    Professor of Medicine and Surgery and Director of Experimental Therapeutics, Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois
    Search for articles by this author
  • William C. Roberts
    Affiliations
    Editor-in-Chief, The American Journal of Cardiology and Baylor University Medical Center Proceedings, Executive Director, Baylor Heart and Vascular Institute of Baylor University Medical Center, and Dean, A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas, Texas
    Search for articles by this author
      This article is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. , Rockville, Maryland.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rozen-Zvi
        • Yahav D.
        • Gheorghiade M.
        • Korzets A.
        • Leibovici L.
        • Gafter U.
        Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis.
        Am J Kidney Dis. 2010; 56: 325-337
        • Schrier R.W.
        • Gross P.
        • Gheorghiade M.
        • Berl T.
        • Verbalis J.G.
        • Czerwiec F.S.
        • Orlandi C.
        • SALT Investigators
        Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
        N Engl J Med. 2006; 355: 2099-2112
        • Dunlay S.M.
        • Gheorghiade M.
        • Reid K.J.
        • Allen L.A.
        • Chan P.S.
        • Hauptman P.J.
        • Zannad F.
        • Maggioni A.P.
        • Swedberg K.
        • Konstam M.A.
        • Spertus J.A.
        Critical elements of clinical follow-up after hospital discharge for heart failure: insights from the EVEREST trial.
        Eur J Heart Fail. 2010; 12: 367-374
        • Gheorghiade M.
        • Abraham W.T.
        • Albert N.M.
        • Gattis Stough W.
        • Greenberg B.H.
        • O'Connor C.M.
        • She L.
        • Yancy C.W.
        • Young J.
        • Fonarow G.C.
        • OPTIMIZE-HF Investigators and Coordinators
        Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.
        Eur Heart J. 2007; 28: 980-988
        • Gheorghiade M.
        • Rossi J.S.
        • Cotts W.
        • Shin D.D.
        • Hellkamp A.S.
        • Piña I.L.
        • Fonarow G.C.
        • DeMarco T.
        • Pauly D.F.
        • Rogers J.
        • DiSalvo T.G.
        • Butler J.
        • Hare J.M.
        • Francis G.S.
        • Stough W.G.
        • O'Connor C.M.
        Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial.
        Arch Intern Med. 2007; 167: 1998-2005
        • Rossi J.
        • Bayram M.
        • Udelson J.E.
        • Lloyd-Jones D.
        • Adams K.F.
        • Oconnor C.M.
        • Stough W.G.
        • Ouyang J.
        • Shin D.D.
        • Orlandi C.
        • Gheorghiade M.
        Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial.
        Acute Card Care. 2007; 9: 82-86
        • Schrier R.W.
        • Gross P.
        • Gheorghiade M.
        • Berl T.
        • Verbalis J.G.
        • Czerwiec F.S.
        • Orlandi C.
        • SALT Investigators
        Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
        N Engl J Med. 2006; 355: 2099-2112

      Linked Article

      • The Difficult Combination of Low Serum Sodium and Heart Failure
        American Journal of CardiologyVol. 108Issue 5
        • Preview
          I read every word of the recent Editor's Roundtable on hyponatremia and the role of vasopressin antagonists,1 a fascinating review of physiology as well as pathophysiology. Franny Moore (a remarkable surgeon!) was the first to show, in the early 1950s, that many chronic diseases, including heart failure, demonstrated the paradox of low serum sodium but an increase in total body sodium and water.
        • Full-Text
        • PDF